Exciting news from Neurona Therapeutics! Today they announced plans to initiate the Phase 3 EPIC clinical trial for NRTX-1001, which is the first investigational human cell therapy for drug-resistant epilepsy. According to their press release, the EPIC trial is anticipated to begin in the second half of 2025 in people living with drug-resistant mesial temporal lobe epilepsy (MTLE), which is the most common type of epilepsy in adults. Learn more: https://lnkd.in/gEYWP-H7
Pediatric Neurologist | Clinical Development & Medical Affairs | Principal Investigator | Neurology, Oncology & Metabolic Diseases Expert
2 周Neurona Therapeutics' innovative use of GABAergic interneurons aims not only to reduce seizures but also to preserve cognitive function, presenting a promising alternative to traditional surgical options. NRTX-1001 can potentially transform treatments for neurological disorders, with a strong emphasis on patient-centered care. This is an exciting time for both patients and the field of regenerative medicine!